Trial Profile
Phase III Study of Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib in Unresectable, Metastatic Biliary Tract Carcinoma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine; Oxaliplatin
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 20 Dec 2011 Results published in the Lancet Oncology.
- 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
- 26 Jun 2010 New trial record